138 related articles for article (PubMed ID: 21133694)
1. Innovations driving biomarker evaluation and use.
Wagner JA
Biomark Med; 2010 Dec; 4(6):779-81. PubMed ID: 21133694
[No Abstract] [Full Text] [Related]
2. Beyond biomarkers: an opportunity to address the 'pharmacodynamic gap' in pediatric drug development.
Kearns GL
Biomark Med; 2010 Dec; 4(6):783-6. PubMed ID: 21133695
[No Abstract] [Full Text] [Related]
3. Applications of 'decisionable' biomarkers in cardiovascular drug development.
Krishna R; Wagner JA
Biomark Med; 2010 Dec; 4(6):815-27. PubMed ID: 21133701
[TBL] [Abstract][Full Text] [Related]
4. From biomarker strategies to biomarker activities and back.
van Gool AJ; Henry B; Sprengers ED
Drug Discov Today; 2010 Feb; 15(3-4):121-6. PubMed ID: 19931413
[TBL] [Abstract][Full Text] [Related]
5. Drug development needs a new brand of science.
Fitzgerald G
Nature; 2010 Dec; 468(7326):869. PubMed ID: 21164436
[No Abstract] [Full Text] [Related]
6. Translational research: 4 ways to fix the clinical trial.
Ledford H
Nature; 2011 Sep; 477(7366):526-8. PubMed ID: 21956311
[No Abstract] [Full Text] [Related]
7. Chutes and ladders on the critical path:comparative effectiveness, product value, and the use of biomarkers in drug development.
Woodcock J
Clin Pharmacol Ther; 2009 Jul; 86(1):12-4. PubMed ID: 19536116
[No Abstract] [Full Text] [Related]
8. Targeted medications. New focus on companion tests.
Reinke T
Manag Care; 2012 Feb; 21(2):35-8. PubMed ID: 22393602
[No Abstract] [Full Text] [Related]
9. A multistep validation process of biomarkers for preclinical drug development.
Freeman WM; Bixler GV; Brucklacher RM; Lin CM; Patel KM; VanGuilder HD; LaNoue KF; Kimball SR; Barber AJ; Antonetti DA; Gardner TW; Bronson SK
Pharmacogenomics J; 2010 Oct; 10(5):385-95. PubMed ID: 19997081
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular pharmacology in the post-blockbuster era.
Brandes RP
Curr Opin Pharmacol; 2010 Apr; 10(2):109-10. PubMed ID: 20202904
[No Abstract] [Full Text] [Related]
11. Counterpoint: Data first.
Golub T
Nature; 2010 Apr; 464(7289):679. PubMed ID: 20360719
[No Abstract] [Full Text] [Related]
12. Translational proteomics: what can you do for true patients?
Belda-Iniesta C; de Castro J; Perona R
J Proteome Res; 2011 Jan; 10(1):101-4. PubMed ID: 20977278
[TBL] [Abstract][Full Text] [Related]
13. Embrace change.
Nature; 2011 Mar; 471(7337):135. PubMed ID: 21390083
[No Abstract] [Full Text] [Related]
14. Metabolomics for early detection of drug-induced kidney injury: review of the current status.
Boudonck KJ; Rose DJ; Karoly ED; Lee DP; Lawton KA; Lapinskas PJ
Bioanalysis; 2009 Dec; 1(9):1645-63. PubMed ID: 21083109
[TBL] [Abstract][Full Text] [Related]
15. Current challenges in pediatric drug development.
Adamson PC
Clin Adv Hematol Oncol; 2008 Dec; 6(12):883-4. PubMed ID: 19209138
[No Abstract] [Full Text] [Related]
16. Implementation of pharmacogenetics in clinical practice is challenging.
van Schie RM; de Boer A; Maitland-van der Zee AH
Pharmacogenomics; 2011 Sep; 12(9):1231-3. PubMed ID: 21919599
[No Abstract] [Full Text] [Related]
17. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
Soares HD
Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
[TBL] [Abstract][Full Text] [Related]
18. Translational medicine and the value of biomarker qualification.
Goodsaid FM; Mendrick DL
Sci Transl Med; 2010 Sep; 2(47):47ps44. PubMed ID: 20811041
[TBL] [Abstract][Full Text] [Related]
19. Regulation and the fate of personalized medicine.
Greenbaum D
Virtual Mentor; 2012 Aug; 14(8):645-52. PubMed ID: 23351321
[No Abstract] [Full Text] [Related]
20. The quest for biomarkers in tuberculosis.
Parida SK; Kaufmann SH
Drug Discov Today; 2010 Feb; 15(3-4):148-57. PubMed ID: 19854295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
